Methylation Analysis of Limited Liquid Biopsy DNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing the methylation status of multiple markers in liquid biopsies are limited by the small amount of target nucleic acids available and high sampling error, making it difficult to accurately assay for methylation status in clinical settings.
Innovation Solution
A method involving the use of methyltransferases to methylate non-cytosine and cytosine nucleotides in a sample, followed by assays to determine the methylation status of target sequences, which enhances the sensitivity and specificity of methylation analysis in limited DNA samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If liquid biopsies are used to analyze methylation status, then noninvasive diagnostics are achieved, but the small amount of target nucleic acids leads to high sampling error and reduced measurement precision
Solution Approach 1:
The patent segments the limited cf-DNA sample into multiple target sequences for parallel analysis. By designing assays that simultaneously detect multiple methylation markers (e.g., SEPT9, NDRG4, BMP3) from the same liquid biopsy sample, the method divides the analytical task into independent detection channels, thereby improving measurement precision without requiring additional sample material.
Solution Approach 2:
The patent applies preliminary enrichment and purification steps to concentrate target sequences from the liquid biopsy sample before methylation analysis. This preliminary action increases the concentration of target nucleic acids, reducing sampling error and improving the reliability of methylation status detection while maintaining the noninvasive nature of the diagnostic approach.
2Measurement precision
If multiple markers are analyzed simultaneously, then diagnostic accuracy is improved, but the complexity of the assay increases
Solution Approach 1:
The patent merges multiple detection functions into a single integrated assay system. By combining multiple methylation-specific probes and detection channels into one assay platform, the method enables simultaneous analysis of multiple markers (SEPT9, NDRG4, BMP3) without requiring separate experimental procedures, thereby improving diagnostic accuracy while controlling assay complexity.
Solution Approach 2:
The patent employs a universal assay platform that can detect multiple different methylation markers using the same basic methodology and reagent system. This multi-functional approach allows the same assay infrastructure to analyze various cancer-related markers, improving diagnostic accuracy across different cancer types without proportionally increasing operational complexity.
3Measurement precision
If the amount of DNA in liquid biopsies is increased, then measurement precision would improve, but the availability of nucleic acids from bodily fluids remains limited
Solution Approach 1:
The patent changes the detection parameters by using highly sensitive methylation-specific assays that can detect low-abundance target sequences. By optimizing assay sensitivity (e.g., using digital PCR or highly specific qPCR methods), the method achieves reliable methylation status detection with limited DNA quantities, transforming the detection capability rather than increasing sample input.
Solution Approach 2:
The patent employs amplification methods (such as PCR) to generate multiple copies of the target sequences from the limited cf-DNA sample. This copying process increases the detectable amount of target nucleic acids without requiring additional biological sample, thereby improving measurement precision while working within the constraints of available nucleic acid quantity.
Data Source
AI summary
Provided are a method for analyzing the methylation status of at least one target sequence in a sample including providing a sample comprising DNA, wherein the DNA comprises at least one target sequence; contacting the sample with at least one methyltransferase that methylates non-cytosine nucleotides; and assaying the sample for the methylation status of one or more cytosine nucleotides in the at least one target sequence, and other related methods.